Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers.
Adult
Aged
Aged, 80 and over
Colon
/ cytology
Colorectal Neoplasms
/ immunology
Humans
Immunotherapy
/ methods
Interleukin-13
/ immunology
Interleukin-13 Receptor alpha1 Subunit
Intestinal Mucosa
/ cytology
Lymphocyte Activation
/ immunology
Middle Aged
Mucosal-Associated Invariant T Cells
/ immunology
Precancerous Conditions
/ immunology
RNA-Seq
Receptors, Interleukin-13
/ metabolism
Rectum
/ cytology
Colorectal cancer
IL-13
MAIT cells
human immunity
tumor immunity
Journal
Immunology and cell biology
ISSN: 1440-1711
Titre abrégé: Immunol Cell Biol
Pays: United States
ID NLM: 8706300
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
14
04
2019
revised:
24
06
2019
accepted:
26
06
2019
pubmed:
20
7
2019
medline:
6
5
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Mucosal-associated invariant T (MAIT) cells are unconventional T cells that recognize antigens derived from riboflavin biosynthesis. In addition to anti-microbial functions, human MAIT cells are associated with cancers, autoimmunity, allergies and inflammatory disorders, although their role is poorly understood. Activated MAIT cells are well known for their rapid release of Th1 and Th17 cytokines, but we have discovered that chronic stimulation can also lead to potent interleukin (IL)-13 expression. We used RNA-seq and qRT-PCR to demonstrate high expression of the IL-13 gene in chronically stimulated MAIT cells, and directly identify IL-13 using intracellular flow cytometry and multiplex bead analysis of MAIT cell cultures. This unexpected finding has important implications for IL-13-dependent diseases, such as colorectal cancer (CRC), that occur in mucosal areas where MAIT cells are abundant. We identify MAIT cells near CRC tumors and show that these areas and precancerous polyps express high levels of the IL-13 receptor, which promotes tumor progression and metastasis. Our data suggest that MAIT cells have a more complicated role in CRC than currently realized and that they represent a promising new target for immunotherapies where IL-13 can be a critical factor.
Identifiants
pubmed: 31323167
doi: 10.1111/imcb.12281
pmc: PMC6790710
doi:
Substances chimiques
IL13 protein, human
0
IL13RA1 protein, human
0
Interleukin-13
0
Interleukin-13 Receptor alpha1 Subunit
0
Receptors, Interleukin-13
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-699Informations de copyright
© 2019 The Authors Immunology & Cell Biology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Références
J Immunol. 2013 Apr 1;190(7):3142-52
pubmed: 23447689
J Allergy Clin Immunol. 2015 Aug;136(2):323-33
pubmed: 25746968
J Immunol. 2015 Oct 1;195(7):3472-81
pubmed: 26297765
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
J Immunol. 2018 Mar 15;200(6):1995-2003
pubmed: 29431692
Nat Rev Immunol. 2015 May;15(5):271-82
pubmed: 25882242
Curr Opin Allergy Clin Immunol. 2018 Feb;18(1):26-31
pubmed: 29257776
Science. 1998 Dec 18;282(5397):2261-3
pubmed: 9856950
Front Immunol. 2017 Dec 15;8:1837
pubmed: 29326714
Science. 1998 Dec 18;282(5397):2258-61
pubmed: 9856949
Nature. 2012 Nov 8;491(7423):254-8
pubmed: 23034650
J Exp Med. 2013 Oct 21;210(11):2305-20
pubmed: 24101382
Nat Med. 2002 Aug;8(8):885-9
pubmed: 12091879
Sci Rep. 2016 Feb 03;6:20358
pubmed: 26837580
Immunol Cell Biol. 2018 May;96(5):507-525
pubmed: 29437263
Immunol Cell Biol. 2018 Jul;96(6):588-597
pubmed: 29393543
Nat Immunol. 2017 Dec;18(12):1321-1331
pubmed: 28991267
Mucosal Immunol. 2017 Jan;10(1):35-45
pubmed: 27049062
Annu Rev Immunol. 2014;32:323-66
pubmed: 24499274
J Immunol. 2018 Mar 1;200(5):1901-1916
pubmed: 29378910
Oncotarget. 2016 Sep 20;7(38):61183-61198
pubmed: 27533463
PLoS Biol. 2009 Mar 10;7(3):e54
pubmed: 19278296
Expert Opin Investig Drugs. 2018 Feb;27(2):179-186
pubmed: 29334288
Nat Commun. 2018 Aug 22;9(1):3350
pubmed: 30135490
Cancer Res. 2012 Jun 1;72(11):2780-90
pubmed: 22505647
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
Nat Commun. 2016 Jun 23;7:11653
pubmed: 27337592
Eur J Immunol. 2014 Jan;44(1):195-203
pubmed: 24019201
Front Immunol. 2017 Aug 30;8:1031
pubmed: 28912775
Nature. 2003 Mar 13;422(6928):164-9
pubmed: 12634786
Semin Immunol. 2017 Aug;32:43-53
pubmed: 28982615
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
Front Immunol. 2018 Jul 30;9:1766
pubmed: 30105031
Front Immunol. 2015 Sep 17;6:466
pubmed: 26441971
Immunity. 2018 Mar 20;48(3):453-473
pubmed: 29562195
Cancer Immunol Immunother. 2015 Dec;64(12):1601-8
pubmed: 26497850
Lancet. 2015 Sep 12;386(9998):1086-96
pubmed: 26383000
FASEB J. 2018 Apr 27;:fj201800052RR
pubmed: 29957059
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Nat Immunol. 2015 Nov;16(11):1114-23
pubmed: 26482978
Blood. 2011 Jan 27;117(4):1250-9
pubmed: 21084709
J Allergy Clin Immunol. 2012 Oct;130(4):829-42; quiz 843-4
pubmed: 22951057